Vaccine Adjuvants Market Size, Share & Trends Analysis Report By Type (Pathogen, Adjuvant Emulsion, Particulate), By Administration (Oral, Intradermal, Intranasal, Intramuscular), By Application, By Region, And Segment Forecasts, 2023 - 2030

Vaccine Adjuvants Market Size, Share & Trends Analysis Report By Type (Pathogen, Adjuvant Emulsion, Particulate), By Administration (Oral, Intradermal, Intranasal, Intramuscular), By Application, By Region, And Segment Forecasts, 2023 - 2030

Vaccine Adjuvants Market Growth & Trends

The global vaccine adjuvants market is expected to reach USD 1.9 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 2.3% from 2023 to 2030. The significance of adjuvant research in the development of vaccines has increased gradually due to inadequate immunogenicity of innovative vaccine antigens. In addition, the growing focus on long-lasting immunization effect against existing and emerging diseases is expected to boost the demand for vaccine adjuvants.

Furthermore, rising prevalence of cervical cancer is anticipated to boost the market. According to NCBI, around 15,000 females die every year due to cervical cancer. There are certain companies developing vaccine adjuvants for this type of cancer in order to enhance the efficacy, such as AS04 adjuvant-adsorbed (human papillomavirus vaccine) by GSK, which boosts the immune response for a longer duration.

Vaccine Adjuvants Market Report Highlights

• The vaccine adjuvants market is segmented based on type into an adjuvant emulsion, pathogen, particulate, combination, and others. The particulate segment held the largest market share in 2022.
• The infectious diseases segment accounted for the largest revenue share of 68.1% in 2022. This large share can be attributed to the gradually growing prevalence of infectious diseases, such as malaria, influenza, hepatitis A, B, & C, and others.
• The administration segment is categorized into oral, intradermal, intranasal, intramuscular, and others. Due to better immune specificity, the intramuscular segment accounted for the largest revenue share of 33.8% in 2022
• North America dominated the market and accounted for the largest revenue share of 41.7% in 2022. The factors contributing to the growth of the market in the North American region are a rise in investments for R&D of new therapeutics and an increase in fatal epidemic diseases.

Please note The report will be delivered in 2-3 business days upon order notification.